Bruce Jacobs, CFA, MBA

Bruce Jacobs, CFA, MBA

Chief Financial OfficeratKymera Therapeutics· In proxies 2021–2025

Pay in FY2025-59% from the year before · Kymera Therapeutics stock +93.4% the same year

Bruce Jacobs, CFA, MBA was paid $2.9M in FY2025 (Dec), down 59%. Kymera Therapeutics stock rose 93.4% that year.

Pay$100 in the stock at the end of FY20 → $126
Pay is from the Summary Compensation Table of each Kymera Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Kymera TherapeuticsPublic company · 5 yr
    • Chief Financial Officer2021 – Present · 5 yrStock in role +42%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?